Kassberg Thomas Richard 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Oct 24, 2023
Insider Transaction Report
Form 4
Kassberg Thomas Richard
CBO & Senior Vice President
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-10-23−39,878→ 0 totalExercise: $6.86Exp: 2023-10-31→ Common Stock (39,878 underlying) - Exercise/Conversion
Common Stock
2023-10-23$6.86/sh+39,878$273,563→ 286,738 total - Sale
Common Stock
2023-10-23$32.78/sh−39,878$1,307,201→ 246,860 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F3]The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.